Dasatinib
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dasatinib is an inhibitor of multiple tyrosine kinases with mechanism of action linked to a broad targeting of Src kinases, and is currently indicated for use as a second line chemotherapeutic agent for treatment of chronic myeloid leukemia resistant to another tyrosine kinase inhibitor, imatinib.15,16”
Citations
Cites
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationSawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationLombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Cited by
Items 101–159 of 159
Alharbi, A., Katary, M., Alshehri, K. M., Asghar, B. H., Omran, M. M., Elshaarawy, R. F. M., Mili, A., Hafez, H. S., & Zakrya, R. (2025) · RSC Advances · doi:10.1039/d5ra00889a · Cited by 7
Integrative genomic analysis facilitates precision strategies for glioblastoma treatment
Chen, D., Liu, Z., Wang, J., Yang, C. G., Pan, C., Tang, Y., Zhang, P., Liu, N., Li, G., Li, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105276 · Cited by 7
Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib
Guerrouahen, B. S., Wieder, E., Blanchard, E. G., Lee, F. Y., Aplenc, R., & Corey, S. J. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22083 · Cited by 7
Synthesis and cytotoxic activity of new 2‐[(3‐aminopropyl)dimethylsilyl]‐5‐triethylsilylfurans
Ignatovich, L., Muravenko, V., Shestakova, I., Domrachova, I., Popelis, J., & Lukevics, E. (2009) · Applied Organometallic Chemistry · doi:10.1002/aoc.1538 · Cited by 7
DualSyn: A dual-level feature interaction method to predict synergistic drug combinations
Chen, Z., Li, Z., Shen, X., Liu, Y., Lin, X., Zeng, D., & Zeng, X. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.125065 · Cited by 6
Biological Drugs: Classic Adverse Effects and New Clinical Evidences
Pina, P. D., Vizzardi, E., Raddino, R., Gavazzoni, M., Caretta, G., Gorga, E., & Cas, L. D. (2012) · Cardiovascular Toxicology · doi:10.1007/s12012-012-9173-z · Cited by 6
Tyrosine Kinase Inhibitors and Cancer Therapy
Madhusudan, S., & Ganesan, T. S. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_3 · Cited by 7
Synthesis and antitumor activity of 3-[(methyl)bis(5-trialkylsilyl-furan-2-yl)silyl]propylamines
Ignatovich, L., Romanov, V. A., Spura, J., Popelis, J., Домрачева, И., & Shestakova, I. (2012) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-012-0940-3 · Cited by 6
Cadar, A. N., Torrance, B. L., Fischler, S. A., Djaba, D. A., Haddad, Z. L., Teskey, D. E., Nagaraju, M., Gorgei, K. A., Lorenzo, E. C., Haynes, L., et al. (2025) · Aging Cell · doi:10.1111/acel.70345 · Cited by 5
Wang, Y., Nan, X., Duan, Y., Wang, Q., Liang, Z., & Yin, H. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117870 · Cited by 5
Dual Kinase Targeting in Leukemia
Mologni, L., Marzaro, G., Redaelli, S., & Zambon, A. (2021) · Cancers · doi:10.3390/cancers13010119 · Cited by 5
Grb2 phosphorylation antagonizes EGFR-driven ras activation by interfering with condensate assembly
Phan, H. T., Lin, C., Stinger, B. L., DeGrandchamp, J. B., Lew, L. J. N., Huang, S. J., & Groves, J. T. (2026) · PLoS ONE · doi:10.1101/2024.09.05.611544 · Cited by 4
A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Liberal, F. D. C. G., Zhang, S., Monteith, S., Buckley, N. E., Parker, E., Haynes, S., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01793-6 · Cited by 4
Gupta, A., Parveen, D., Azam, F., Shaquiquzzaman, M., Akhter, M., Jaremko, M., Emwas, A.-H. M., Khan, M. A., Parvez, S., Khanna, S., et al. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101937 · Cited by 4
Recent Review on 1,3-Thiazole Derivatives as Therapeutic Targeted for Anticancer Activity
Mishra, S., & Sahu, A. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230809153027 · Cited by 3
Finiuk, N. S., Klyuchivska, O., Ivasechko, I., Mitina, N., Ostapiuk, Y. V., Obushak, M. D., Zaichenko, A., Babsky, A. M., & Stoika, R. S. (2021) · The Ukrainian Biochemical Journal · doi:10.15407/ubj93.02.039 · Cited by 3
Targeting cytoskeletal phosphorylation in cancer
Llorente-González, C., González-Rodríguez, M., & Vicente‐Manzanares, M. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00047 · Cited by 3
Zhang, Z.-H., Zeng, B.-F., Song, Z.-X., Ying-yu, Y., Zhang, K.-Y., Du, X., Zhang, L.-L., & Cai, D. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02971-2 · Cited by 2
Kleemann, A. (2014) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.r22_r01 · Cited by 2
Cancer Drug Resistance: Targets and Therapies
Zdrazil, B., & Ecker, G. F. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc215 · Cited by 2
Development of BCR-ABL1-positive ɤδ T-cell leukemia after treatment for thymoma type B1
Terao, T., Ashimine, H., Tsuyama, N., Ikeda, D., Kuzume, A., Tabata, R., Tsushima, T., Miura, D., Narita, K., Takeuchi, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1856834 · Cited by 1
A generative deep neural network for pan-digestive tract cancer survival analysis
Xu, L., Lan, T., Huang, Y., Wang, L., Lin, J., Song, X., Tang, H., Cao, H., & Chai, H. (2025) · BioData Mining · doi:10.1186/s13040-025-00426-z · Cited by 1
Lauria, A., Monica, G. L., Gentile, C., Mannino, G., Martorana, A., & Peri, D. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.013 · Cited by 1
Bhanumathy, K. K., Abuhussein, O., Vizeacoumar, F. S., Freywald, A., Vizeacoumar, F. J., Phenix, C. P., Price, E. W., & Cao, R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1740-3_18 · Cited by 1
An overview of in silico methods used in the design of VEGFR-2 inhibitors as anticancer agents
Bhandare, R. R., Bakchi, B., Sigalapalli, D. K., & SHAIK, A. B. (2022) · Physical Sciences Reviews · doi:10.1515/psr-2018-0163 · Cited by 1
Fernández, A. (2016) · Soft and biological matter · doi:10.1007/978-3-319-30852-4_12
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2017) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub3
Developing of Micellar Drug Carriers for the Treatment of Breast Cancer Bone Metastasis
Liu, T. (2018) · DigitalCommons@UNMC
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2022) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub4
Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263.ch8
Guan, W. P., Shi, Y., Xu, J., Wang, X., Xiao, J., & Xie, L. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3610
Hwang, J. M., Shin, Y.-C., Amasanaa, E., Kim, N., Hong, S., Choi, I. S., Kim, Y. H., Seong, H., Myung, K., Lee, Z., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00308
Lobanov, V. A., Rossomakhina, N., Kazakova, E., Zherdeva, V. V., & Makarov, V. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70195
Wrapper Drugs as Therapeutic Editors of Side Effects
Fernández, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-11792-3_12
Fernández, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16850-0_12
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116040
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116061
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116049
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116058
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116028
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116043
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116037
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116052
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116046
Angel, C. Z., Beattie, S., Hanif, E. A. M., Ryan, M. P., Guerra Liberal, F. D. C., Zhang, S.-D., Monteith, S., Buckley, N. E., Parker, E., Haynes, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27116034
Eggert, A. (2025) · UTUPub (University of Turku)
Synthesis, ct-DNA Binding and Molecular Docking Studies of 2-aminothiazole-based CompoundsPreprint
Vassiliou, S., Terzi, E. D., Kakokefalou, V., Dimopoulou, A., & Detsi, A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5709648
Redundant roles of YES and SRC tyrosine kinases in driving malignant peripheral nerve sheath tumorsPreprint
Zereg, E., Voisin, L., Courcelles, M., Brochu, S., Gombos, M., Bonneil, É., Grenier, K., Jung, S., Perreault, C., Tirode, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.17.706384
Etude des rétrotransposons LINE-1 dans la leucémie myéloïde chronique
Josselin, M. (2012) · theses.fr (ABES) · doi:10.70675/bc47fd06zd375z4cbcz8dbez5fac13e7c5ae
Airiau, K. (2012) · theses.fr (ABES) · doi:10.70675/bf87e163z09f5z4e4bzb5b2z45c3aa05c104 · Cited by 1
Rôle de l'adrénomédulline dans le Mésothéliome pleural malin et le cancer bronchopulmonaire
Tounsi, A. (2014) · theses.fr (ABES) · doi:10.70675/b9b82f0az4fa4z4e5czbea5z12e3b53ee430
Wolf, K. M. P., Angelidakis, E., Künzli, D., Lauer, D., Brunner, M., Cambria, A., Vats, D., Maurer, B., Vogel, V., & Chabria, M. (2026) · Matrix Biology Plus · doi:10.1016/j.mbplus.2026.100204
Research Progress on Small-Molecule Inhibitors Targeting Salt-Induced Kinases
Li, S., & Xia, W.-T. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025603647
BindingDB (2012) · UC San Diego · doi:10.7270/q24j0g05
BindingDB (2010) · UC San Diego · doi:10.7270/q25x28qz
Metadata
- Authors
- Kantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- IQVIA (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-09
- Volume
- 5
- Issue
- 9
- Pages
- 717-718
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4247947439
- Cited by
- 149
- References
- 11
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 19 · 2023: 11 · 2022: 14 · 2021: 13 · 2020: 5 · 2019: 6 · 2018: 3 · 2017: 3 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 6
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, tyrosine kinase inhibitors, chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, imatinib resistance, drug approval, BCR-ABL
- MeSH terms
- Dasatinib, Administration, Oral, Adult, Clinical Trials as Topic, Humans, Pyrimidines, Thiazoles, Molecular Structure, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Treatment Outcome, Drug Approval, Guideline Adherence, Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.